AVTX · CIK 0001534120 · operating
Avalo Therapeutics is a clinical-stage biotechnology company focused on developing therapies for immune dysregulation disorders. The company's lead program, AVTX-009, is a humanized monoclonal antibody targeting interleukin-1ß currently in phase 2 clinical trials for the treatment of inflammatory diseases. The company does not currently generate product revenues and operates primarily through research and development activities.
Founded in 2011 and formerly known as Cerecor Inc., the company rebranded to Avalo Therapeutics in August 2021. Avalo is headquartered in Rockville, Maryland, and operates with a small organizational footprint of approximately 23 full-time employees. The company is incorporated in Delaware and trades on the Nasdaq exchange.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-20.91 | $-7.94 | +81.7% | |
| 2023 | $-114.00 | $-114.00 | -2473.4% | |
| 2022 | $-4.43 | $-4.43 | — | |
| 2021 | — | — | — | |
| 2020 | — | — | — | |
| 2019 | — | — | — | |
| 2018 | $-1.20 | $-1.20 | -990.9% | |
| 2017 | $-0.11 | $-0.11 | — | |
| 2016 | — | — | — | |
| 2015 | — | — | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2024-12-31 | 2025-03-20 | 0001628280-25-013986 | SEC ↗ |
| 2023-12-31 | 2024-03-29 | 0001628280-24-013786 | SEC ↗ |
| 2022-12-31 | 2023-03-29 | 0001628280-23-009630 | SEC ↗ |
| 2021-12-31 | 2022-03-02 | 0001628280-22-004671 | SEC ↗ |
| 2020-12-31 | 2021-03-08 | 0001628280-21-004162 | SEC ↗ |
| 2019-12-31 | 2020-03-11 | 0001628280-20-003395 | SEC ↗ |
| 2018-12-31 | 2019-03-18 | 0001628280-19-003078 | SEC ↗ |
| 2017-12-31 | 2018-04-02 | 0001628280-18-003890 | SEC ↗ |
| 2016-12-31 | 2017-03-14 | 0001628280-17-002566 | SEC ↗ |
| 2015-12-31 | 2016-03-23 | 0001558370-16-004299 | SEC ↗ |